Latanoprost Stadafarma (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary body, increasing uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management.

The prescribed dose of Latanoprost Stadafarma is determined by the treating eye‑care professional. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Latanoprost is a prostaglandin analog, generally considered more effective at lowering intra‑ocular pressure than many beta‑blockers and carbonic anhydrase inhibitors, with once‑daily dosing. Its side‑effect profile includes ocular changes such as iris darkening, which differ from the systemic effects seen with some alternatives.

Latanoprost Stadafarma should be stored at room temperature, below 25 °C, in the original packaging. Protect the bottle from light, moisture, and extreme temperatures to maintain stability and potency.

The medication is applied as a single drop into the affected eye(s) once daily, preferably in the evening. Patients should wash their hands, avoid touching the tip of the bottle to the eye or any surface, and close the eye gently after instillation.

Serious risks, though rare, include uveitis, corneal edema, paradoxical increase in intra‑ocular pressure, and severe allergic reactions. Patients should seek immediate medical attention if they experience sudden vision loss, intense eye pain, or signs of systemic hypersensitivity.

Latanoprost Stadafarma should be avoided in individuals with known hypersensitivity to latanoprost or any excipients, active ocular infections, or inflammation. Caution is also advised for patients with a history of uveitis or corneal disease, and the prescriber should evaluate suitability.